December 2, 2022

Dear Colleagues,

Thank you to Sarah Infantino, Patient Services Manager on NP14 at Smilow Cancer Hospital, for authoring today’s guest blog on "Connecting with Purpose" and highlighting the contributions of Cathy Lyons, a pioneering leader in oncology nursing. I knew Cathy well; she was an exceptional clinician and leader, and a truly remarkable individual. As the holidays approach, it is a particularly meaningful time to pause, remember, and reflect.

Connecting with Purpose

Recently we honored Catherine A. Lyons with the Excellence in Oncology Nursing Leadership Award in her name, as well as a Smilow Nursing Grand Rounds with Wendy Garvin Mayo, APRN, ANP-BC, presenting “Lead with Purpose.” What a perfect topic to honor a nurse leader that absolutely led and lived with purpose in every step and action she took. When Cathy entered a room there was a palpable presence, and that energy spoke to her unwavering passion and purpose: to lead our cancer hospital in delivering the highest quality, evidenced-based care, compassionately and consistently; and to have the nursing voice at the decision-making table.

The inaugural Catherine A. Lyons Excellence in Oncology Nursing Leadership Award was presented to Irene Piazza, MSRN, PhD, Clinical Program Manager, Smilow Cancer Hospital Care Center in Greenwich, and I can imagine Cathy’s smile and her words of recognition and praise for Irene posthumously. Irene’s grace, gratitude, and recognition of her staff and leadership team radiated during her acceptance speech. One nominator noted, “Sometimes it is really easy for nurses to become so overwhelmed by the chaos of the day that we forget to stop and really listen to our patients. Irene is an incredible role model in showing us that no matter how busy we are, our patients always come first.”

It was a powerful reminder for me to take time to reflect and connect with my purpose daily. These last few years have been long for us all, often in different ways, but also in some of the same. We struggle at times with stress management and recovery, both personally and professionally from all the pandemic has changed in our world. It seems we are frequently asked to do more, sometimes with less resources and time, which Wendy Garvin Mayo, APRN, ANP-BC, presented at our Smilow Nursing Grand Rounds on "Lead with Purpose."
more, sometimes with less resources and time, which Wendy Garvin Mayo referenced as the cause of stress and the continued stress cycle during her presentation.

How do we get out of that cycle? One way is to remember our purpose. To connect to our why. I have wanted to be a nurse since before I can remember, using my medical kit to examine creatures and humans near and far when I was 3 and 4. But my purpose is connected to my grandmother and her courageous, sometimes messy, sometimes funny, ultimately life-ending journey with cancer. I know in my bones the nurses and provider teams that took care of her and our family made the worst thing we were experiencing less scary, and less traumatic. They held us, twinkling with delight when she would wear her flamingo hat to treatment on her beautiful bald head, and in the end the “hospice angels” as she referred to them, guided her peacefully in passing.

The work we do is challenging and sometimes feels insurmountable, but each one of us has a purpose behind why we entered this field and why we are here at Smilow. In Cathy Lyons’ honor, or another inspiring mentor in your career, please take the time to reflect and to connect to that energy source—with that shared connection all things are possible.

Sarah Infantino, MSHA, RN, OCN
Patient Service Manager
Women’s Oncology NP14

Announcements

Barbara Burtness, MD, Named Chief Translational Research Officer
I am pleased to announce the appointment of Barbara Burtness, MD, Professor of Medicine (Medical Oncology), as Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research for Yale Cancer Center. Dr. Burtness’ experience, leadership, and mentorship in clinical and translational research will benefit investigators across Yale Cancer Center as we work to build a robust translational research platform for all types of cancer. We are profoundly indebted to Roy S. Herbst, MD, PhD, for his leadership of translational research over the past decade. Dr. Herbst has assumed new responsibilities as a Deputy Director of Yale Cancer Center.

Dr. Burtness is the founding director of the Yale Head and Neck Cancer Specialized Program of Research Excellence (SPORE). She is also an internationally recognized leader in the treatment of head and neck cancer, having led numerous clinical trials, including an international phase III trial that led to FDA approval of immunotherapy in first-line treatment of head and neck cancer. She is principal investigator of a laboratory funded by NCI, NIDCR, DoD, Stand Up to Cancer, and the Fanconi Anemia Research Foundation, with whom she has enjoyed a close and productive relationship.

Barbara Burtness, MD, Named Chief Translational Research Officer

Advancing Novel Pancreatic Cancer Research

Biomarkers could determine the need for chemotherapy in young patients with ER+ breast cancer

Barbara Burtness, MD, Named Chief Translational Research Officer

Advancing Novel Pancreatic Cancer Research

Biomarkers could determine the need for chemotherapy in young patients with ER+ breast cancer

Hospice & Palliative Care Month Q&A with Ismaele Jacques

Read More

Advancing Novel Pancreatic Cancer Research

Biomarkers could determine the need for chemotherapy in young patients with ER+ breast cancer

Watch Now

Lung Cancer Awareness Q&A with Roy Herbst, MD, PhD

Read More

Biomarkers could determine the need for chemotherapy in young patients with ER+ breast cancer

Lung Cancer Awareness Q&A with Roy Herbst, MD, PhD

Biomarkers could determine the need for chemotherapy in young patients with ER+ breast cancer
Foundation studying synthetic lethal therapies for head and neck cancer. Her recent research on KRAS mutations has identified new pathways for resistance in the treatment of lung cancer, expanding her laboratory impact to the 30% of patients with non-small cell lung cancer identified as having KRAS mutations.

Dr. Burtness joined Yale Cancer Center and Smilow Cancer Hospital in 2014 from Fox Chase Cancer Center. She is the division chief for head and neck cancers/sarcoma, co-leader of the Developmental Therapeutics Research Program, and Interim Associate Director for Diversity, Equity and Inclusion at Yale Cancer Center. Nationally, Dr. Burtness chairs the ECOG-ACRIN Head and Neck Therapeutics Committee and serves on the SITC Head and Neck Guidelines Committee and the NCI Head and Neck Cancer Steering Committee.

Yale Research at SABCS and ASH
Our Breast Cancer and Hematology teams will close out 2022 with participation in annual meetings this month. Beginning December 6, our Breast Cancer team will participate in the annual San Antonio Breast Cancer Symposium (SABCS). Our Hematology Program will participate in the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans starting on December 10 with presentations on clinical and research advances for the treatment of hematologic malignancies. Please review the presentations from Yale scheduled to be presented at SABCS and ASH and support your colleagues during their presentations.

SABCS Participation
ASH Participation

Notables

Bruce McGibbon, MD, Associate Professor of Clinical Therapeutic Radiology; Medical Director, Greenwich Hospital Radiation Oncology, is the recipient of the 2022 Norm Roth Leadership Award from Greenwich Hospital. The award is given by the Medical Staff at Greenwich Hospital in honor of the retirement of Norm Roth, and in appreciation for his service to Greenwich Hospital, and in recognition of emerging leaders at the hospital. Dr. McGibbon is described in the nomination as a skilled, helpful, and extremely trustworthy colleague-and-advisor; a leader who inspires people to be better...while also making them feel good about themselves. His leadership in Radiation Oncology at Greenwich Hospital has served as a model for other YNHHS Radiation Oncology facilities. Dr. McGibbon has been an active advocate for the new cancer center project and has been instrumental in developing new programs to improve the quality of life for patients, staff, and doctors within his department, and potentially beyond.

The Lustgarten Foundation announced Mandar Muzumdar, MD, Assistant Professor of Genetics and of Medicine (Medical Oncology), as the recipient of a 2022 Innovation and Collaboration Program Grant. The funding will support his study titled "Dietary oleic acid reprograms pancreatic lipid metabolism to drive cancer development."

Michael Cecchini, MD, Assistant Professor of Medicine (Medical Oncology), was appointed to the Colon Task Force of the NCI Gastrointestinal Steering Committee.

Follow us!
Sara Raboin, has been promoted to the position of **CTO Operations Director**. In this new role, she will oversee Clinical Operations, the Clinical Research Support Lab, and Regulatory Affairs for the Clinical Trials Office. Sara has been a calm and steady force during many challenging times during her short tenure and her contributions to our CTO have been tremendous.

**Tara Sanft, MD**, Associate Professor of Medicine (Medical Oncology), Chief Patient Experience Officer, and Medical Director of the Survivorship Clinic at Smilow Cancer Hospital, has been accepted into the **Faculty-in-Training program** (FIT) at the **Academy of Communication in Healthcare** (ACH). This is a competitive program that will provide highly specialized training in four core domains: small group facilitation, coaching, workshop content and development, and personal awareness.

The **American Brain Tumor Association** (ABTA) recently announced funding of Discovery Grants to **Henk De Feyter, PhD**, Assistant Professor of Radiology and Biomedical Imaging, and **Jacky Yeung, MD**, Assistant Professor of Neurosurgery. Discovery grants are one-year, $50,000 grants supporting high-risk, innovative approaches that hold potential to change current diagnostic or treatment standards of care.

**Michael Galbicsek**, Administrative Manager of the Clinical Trials Office, was recently honored by Yale University with a **Linda K. Lorimer Award for Distinguished Service** in honor of his leadership and excellent work to create a COVID+ research site using trailers during the beginning of the pandemic. Michael led a team and transformed a construction trailer into a HEPA-filtered negative pressure environment to allow outpatient study participants who were COVID-positive and actively symptomatic to participate in treatment studies. The Lorimer Awards honor Yale staff members whose outstanding contributions and accomplishments further Yale’s core mission in exceptional ways.

**Maryam Lustberg, MD, MPH**, Associate Professor of Medicine (Medical Oncology), Director, Center for Breast Cancer, and Chief of Breast Medical Oncology, presented on burnout, digital health, and health disparity at the **Multinational Association of Supportive Care in Cancer (MASCC)** Best of MASCC meeting in Korea last week. Dr. Lustberg is the current President of MASCC.

**David Braun, MD, PhD**, Assistant Professor of Medicine (Medical Oncology) and Louis Goodman and Alfred Gilman Yale Scholar, presented the keynote lecture at the **Society of Urologic Oncology** earlier this week on "Neoadjuvant Trials: What We Can Learn."

**Jessica M. Stempel, MD**, a second-year fellow in the Yale Medical Oncology-Hematology Fellowship Program, has received the **Patterson Trust Mentored Research Award** to support her research in "Treatment Pattern and Outcomes of Patients with Acquired Aplastic Anemia and Related Malignancies in the United States." Dr. Stempel’s mentors for this project include Xiaomei Ma, PhD, Professor of Epidemiology (Chronic Diseases) and Co-Leader of the Cancer Prevention and Control Research Program, and Nikolai Podoltsev, MD, PhD, Associate Professor of Internal Medicine (Hematology) and Alfred Lee, MD, PhD, Professor of Medicine.
Paul Stockhammer, MD, PhD, a third-year internal medicine resident at the Yale School of Medicine, and a research member of the Politi Lab, received the Distinguished Young Investigator Research Award at this year's EGFR Resisters Research Summit in Chicago, IL, for his work entitled “Co-occurring Alterations in Multiple Tumor Suppressor Genes Associate with Outcomes in Patients with EGFR-mutant Lung Cancer.” The award recognizes outstanding young investigators presenting their unpublished research at the annual EGFR Resisters Research Summit. Dr. Stockhammer is co-mentored by Drs. Katerina Politi and Sarah Goldberg, where he focuses on EGFR-driven lung cancer and drug resistance, with emphasis on studying relationship between EGFR and co-occurring tumor suppressor gene alterations.

Giulia Biancon, PhD, has been awarded the 2022 Italian Scientists & Scholars in North America Foundation (ISSNAF) Young Investigator Paola Campese Award. She was presented with the award on Monday, November 7th during a ceremony at the Italian Embassy in Washington, DC. Dr. Biancon is a Postdoctoral Associate in the lab of Stephanie Halene, MD, PhD, where her research is focused on dissecting the role of splicing factor mutations in myeloid malignancies merging molecular and computational biology.

Roy S. Herbst, MD, PhD, Deputy Director of Yale Cancer Center, recently participated in the National Academies of Sciences, Engineering and Medicine Addressing Resistance to Immune Modulator Therapies for Cancer Treatment: A Workshop in Washington, DC, sharing an update on Criteria to Assess Cancer Immunotherapy Combinations in Early-Phase Clinical Trials. He then joined Patricia LoRusso, DO, to present and mentor at the BMSF-AACR Design and Implementation of Clinical Trials Workshop.

Natalia Neparidze, MD, Associate Professor of Medicine (Hematology), participated as an invited speaker on November 3 at the International Myeloma Congress in Italy and presented on “Changed Approaches and Follow-ups in the Myeloma Patients in the COVID-19 Era.”

Kristina Capretti, RN, of the Smilow Cancer Hospital Care Center in Greenwich has joined the Board of Directors of the Susan D. Flynn Oncology Nursing Development Program, Inc., a local nonprofit that is playing a crucial role in developing the next generation of oncology nurses.

The Genomics, Genetics and Epigenetics Research Program welcomes Curtis Pickering, PhD, Associate Professor of Surgery (Otolaryngology). Dr. Pickering’s lab studies the translational genomics of head and neck squamous cell carcinoma (HNSCC) and other squamous tumors with the goal of improving outcomes for patients with
head and neck cancer. His approach is to try to understand the HNSCC genome and use that knowledge to identify genes and pathways that are key to the biology of HNSCC. That biological understanding can then be used to identify biomarkers and/or therapeutic targets, which can be translated back to the clinic to improve patient care. Dr. Pickering's lab uses genomic, computational, and cell and molecular biology techniques in human tissue and cell line models.

Diversity, Equity, and Inclusion

Albertus Magnus Cancer Research Student Science Day
Recently, Albertus Magnus College Professors Mark Barreuther and Rebecca Brogan brought seven Albertus Magnus undergraduate students to Yale Cancer Center for the first Albertus Magnus Cancer Research Student Science Day. Yale Cancer Center graduate student Mariana Do Carmo, postdocs Sebastian Cruz Gomez and Ece Koçak, medical oncology fellow David Schoenfeld, and medicine resident David Su gave presentations about their paths to becoming a cancer researcher or physician-scientist, talked about their cancer research projects, and presented clinical cases. The students then toured the King and Burtness labs.

This event was a wonderful introduction to cancer research and careers in cancer research for students from Albertus, and the first Albertus undergraduate to do a research internship at Yale Cancer Center will join us this month. Albertus Magnus College is our near neighbor in New Haven and is a minority-majority institution highly ranked for its impact on social mobility. We are delighted to partner with Albertus Magnus College in introducing a new generation to cancer research.

Dr. Elizabeth Prsic Leads Initiative to Support Breastfeeding
Elizabeth Prsic, MD, Firm Chief for Medical Oncology and Director of Adult Inpatient Palliative Care at Smilow Cancer Hospital, along with former Yale fellow Julia Foldi, MD, PhD, received a Women Faculty Forum grant to identify and reduce barriers to breast milk expression among medical trainees. Their survey of over 150 Graduate Medical Education (GME) House Staff identified greater awareness of the needs of lactating individuals, dedicated lactation space, refrigerator access, and use of hands-free pumps as areas for increased support. With funding from the Women Faculty Forum Seed Grant, Dr. Prsic’s team was able to purchase $2,000 worth of hands-free, hospital grade, closed system pumps for GME House Staff.

Employee Profile: Jon Gorton, RN
As a registered nurse at the Smilow Cancer Hospital Care Center in Derby, Jon Gorton is known as the go-to person in the office. He is always going the extra mile for patients. Read More

On Yale Cancer Answers, join us in honor of Lung Cancer Awareness Month. Interventional pulmonologists Drs. Sanket Thakore and Kyle Bramley discuss new innovation in the diagnosis of lung cancer using robotic bronchoscopy technology, which is currently only available at Smilow Cancer Hospital. Listen on Connecticut Public Radio or download our podcast from iTunes.

Read More

November is Stomach Cancer Awareness Month. Chair of the Department of Surgery at Yale School of Medicine and Chief of Surgery at Yale New Haven Hospital, Dr. Nita Ahuja also serves on the Scientific Advisory Board for No Stomach for Cancer, a non-profit patient advocacy organization focused on awareness and education about stomach cancer.

Dr. Ahuja says, "No Stomach For Cancer helps individuals understand what stomach or gastric cancer is and recognize its symptoms, which is one of our key priorities. We really try to do a great job of sharing information with the general public and the medical community to encourage earlier diagnoses and improve survival rates.

Knowing your family history of cancer and being aware of potential risk factors are excellent places to begin. Currently, the 5-year survival rate for Stage IV stomach cancer is only 4%, and the overall 5-year survival rate is about 29%."
always going the extra mile for patients and offering to help when colleagues have questions or when the team is understaffed.

The Care Center in Derby sees 10-20 patients a day for treatments ranging from infusions and subcutaneous injections, to injections to help improve blood counts. On average, Derby has a staff of about 15, but with the recent departure of a charge nurse, Jon has been handling those responsibilities in addition to his own, as well as precepting a new nurse. As busy as his days may be, he loves his job and wouldn’t have it any other way.

In fact, Jon did not go into nursing directly from college. He had pursued another career that he did not enjoy until his wife, who is also a nurse, nudged him to explore nursing as a new career. He agreed and went back to school, completing his clinical rotation at Smilow on NP15. Upon graduating from the Certificate Entry Into Nursing (CEIN) program at UConn Waterbury, a one-year accelerated degree program for registered nursing, Jon was offered a job on NP15.

“Jon is a great coworker; he always has a positive attitude and outlook on even the most challenging situations,” says Jamie Piazza, patient financial access counselor for the Smilow Cancer Hospital Care Centers in Derby, Waterbury, and Torrington. She says, “Jon never shies away from tough scenarios and offers help whenever needed. He has been an exceptional resource for me since I started with Smilow. He also makes it a point to go above and beyond for his patients and truly cares for them. He makes them feel comfortable and makes himself a resource for them even after they have left the clinic.”

Jon has been very happy since making his career change and believes there is a niche in nursing for everyone. And after working on NP15 for a few years, he has found his niche at Derby, forming strong relationships with the patients and helping his colleagues when needed.

Recent Publications

Plaz Torres MC, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG.
**Diabetes Medications and Risk Of HCC**
Read More

Oh SJ, Butler PD.
**Ensuring Both Accessibility and Usability of Breast Cancer Care**
*Science Direct.*  
Read More
In honor of Hospice & Palliative Care Month, Dr. Alex Choi of the Palliative Care Program at Smilow Cancer Hospital participated in a Q&A and shared insights into the benefits of palliative care and how the field has evolved in recent years.

The Southern Connecticut Conference (SCC) girls' swim and dive teams held lap-a-thons throughout the month of October in honor of Breast Cancer Awareness Month and to raise money for Lion Heart. Take a look at these photos of swimmers from ages 7-18. The girls raised over $20,000! Thank you to the swim teams for their time, expertise, energy and hearts to raise money for Lion Heart breast cancer research grants, which will be awarded to Yale Cancer Center and Smilow Cancer Hospital scientists in mid-December for research to be conducted for one year beginning in January, 2023.
Effect of Androgen-Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients
*Cancer Investigation.*
*Read More*


*Read More*


*Read More*

Potnis KC, Ross JS, Aneja S, Gross CP, Richman IB.

*Artificial Intelligence in Breast Cancer Screening: Evaluation of FDA Device Regulation and Future Recommendations JAMA Internal Medicine.*
*Read More*

Check DK, Baggett CD, Kim K, Merlin JS, Oeffinger KC, Winn AN, Roberts MC, Robinson T, Dinan MA.

*Concurrent Prescribing of Opioids with Other Sedating Medications After Cancer Diagnosis: A Population-Level Analysis Supportive Care in Cancer.*
*Read More*


*Placing Human Gene Families into Their Evolutionary Context Human Genomics, 16(1):56.*
*Read More*

Jacobs JW, Guarente J, Chooljian DM, Booth GS, Adkins BD.

*Read More*

Xie Z, Chen EC, Stahl M, Zeidan AM.

*Prognostication In Myelodysplastic Syndromes (Neoplasms): Molecular Risk Stratification Finally Coming of Age Blood Reviews.*
*Read More*

Moen JM, Mohler K, Rogulina S, Shi X, Shen H, Rinehart J.

*Read More*

---

The 13th annual Beach Jam for Cancer Patient Assistance, a day-long celebration of live bands, food, and fun, was held in August at the Westbrook Elks Club. The event raised a record amount for patient assistance at Smilow Cancer Hospital. Pictured at the recent check presentation are just a fraction of the countless volunteers who made this event such a success! Thank you all for your support of our patients at Smilow Cancer Hospital!

---

@JeffTownsend @YaleCancer Grand Rounds discusses the role of #mutagenic origins of individual tumors and tumor types in answering a question many #cancer patients face which is, "Why Me?" Watch now

Tonight at 7:30pm on @YaleCancer Answers, Drs. Sanket Thakore and Kyle Bramley discuss new innovation in the Palliative & hospice providers are here to provide comfort & care to our patients” says Ismaele Jacques, APRN-BC, MSN, PhD, for #HospiceandPalliativeCareMonth

Tonight at 7:30pm on @YaleCancer Answers, Drs. Sanket Thakore and Kyle Bramley discuss new innovation in the Palliative & hospice providers are here to provide comfort & care to our patients” says Ismaele Jacques, APRN-BC, MSN, PhD, for #HospiceandPalliativeCareMonth

Reid EA, Abathun E, Diribi J, Mamo Y, Wondemagegnhu T, Hall P, Fallon M, Grant L. **Early Palliative Care in Newly Diagnosed Cancer In Ethiopia: Feasibility Randomised Controlled Trial And Cost Analysis** *BMJ Supportive & Palliative Care*. Read More


Zhan PL, Canavan ME, Ermer T, Pichert MD, Li AX, Maduka RC, Kaminski MF, Boffa DJ. **Nonregional Lymph Nodes as the Only Metastatic Site in Stage IV Esophageal Cancer** *Science Direct, JTO Clinical and Research Reports, 3*(12):100426. Read More


Li X, Yan H, Wu J, Zhang L. **Tobacco Smoking Associates with NF1 Mutations Exacerbating Survival Outcomes in Gliomas** *Biomarker Research, 10*(1):78. Read More

Kyle Bramley discuss new innovation in the diagnosis of lung cancer using robotic bronchoscopy technology @SmilowCancer. Listen live on @wnpr or download our podcast from @iTunes.

"Knowing your family history of cancer & being aware of risk factors are excellent places to begin. Currently, the 5-yr survival rate for Stage IV stomachcancer is 4% & the overall 5-year survival rate is ~29%.”

Dr. Maryam Lustberg @maryam_lustberg will present "Innovations in Supporting Patients, Caregivers, and the Oncology Healthcare Workforce" at Best of MASCC @CancerCareMASCC in Korea on November 26.

We are grateful for our amazing physicians, nurses & staff who work tirelessly to provide the very best in cancer care and treatment to our patients and their families. #HappyThanksgiving to our patients, their families, and our entire SmilowCancer & @YaleCancer community!

"We are all #leaders at various points in our career and it’s important to take ownership of whatever you’re leading at the time,” said Dr. Pamela Kunz @PamelaKunzMD in this @OncologyTimes story on women in #leadership.

"It takes a team to care for our patients. #Cancer is such a tremendous adversary so we must work together to treat patients in the most effective way,” says Roy Herbst, MD, PhD @DrRoyHerbstYale in this Q&A: http://bit.ly/3hLka2I

Tonight at 7:30pm on Yale Cancer Answers, join us in honor of #Movember as Dr. Katherine Rotker @DrRotker & Dr. Stanton Honig @shonig discuss male #fertility & sexual medicine. Listen on @wnpr or download our podcast from @iTunes.

"Early #palliativecare has shown to QOL, symptoms of depression, and
Prediction Of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancer: Development And External Validation Of A Multi-Institutional Model
Science Direct, Journal of Thoracic Oncology, online ahead of print.
Read More

Potnis KC, Di M, Isufi I, Gowda L, Seropian SE, Foss FM, Forman HP, Huntington SF. 
Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Adults with Relapsed or Refractory Follicular Lymphoma
Blood Advances.
Read More

Mandell JD, Fisk JN, Cyrenne E, Xu ML, Cannataro VL, Townsend JP. 
Not Only Mutations But Also Tumorigenesis Can Be Substantially Attributed To DNA Damage From Reactive Oxygen Species In RUNX1::RUNX1T1-Fusion-Positive Acute Myeloid Leukemia
Leukemia.
Read More

Black EM, Joo YK, Kabeche L. 
Keeping Relapse in Chk: Molecular Mechanisms of Chk1 Inhibitor Resistance in Lymphoma
Biochemical Journal, 479(22):2345-2349.
Read More

Gaddy J, Gross C. 
Addressing Racial, Ethnic, and Age Disparities in Cancer Clinical Trial Enrollment: Time to Stop Tinkering Around the Edges
JAMA Oncology.
Read More

Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
Read More

Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit
JCO Precision Oncology, 6:e2200454.
Read More

Plaz Torres MC, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG. 
Diabetes Medications and Risk Of HCC

NCCN Tumor Boards

NCCN offers numerous free continuing education opportunities throughout the year, including the Monthly Oncology Tumor Board series. These live and endured webinars are designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other healthcare professionals who manage patients with cancer.

Upcoming live webinar topics include:

- Esophageal and Esophagogastric Junction Cancers: Postoperative Therapy in Patients with Residual Disease – November 9
- Management of Early-Stage Breast Cancer – December 14

Learn More

Calendar

Yale Cancer Answers
December 4; 7:30 PM
Health Disparities and Substance Use among Youth
Grace Kong, PhD | Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C)
Learn More
Diabetes Medications and Risk Of HCC
*Hepatology, 76*(6):1880-1897.

Read More

Oh SJ, Butler PD.
**Ensuring Both Accessibility and Usability of Breast Cancer Care**
*Science Direct.*

Read More

Raja J, Madoff DC.
**Oncopharmacology in Interventional Radiology**

Read More

**Tobacco Promotion Restriction Policies on Social Media**
*Tobacco Control.*

Read More

**Patterns And Trends in The Cause of Death for Patients with Endometrial Cancer**
*JNCI Cancer Spectrum,* online ahead of print.

Read More

Poghosyan H, Ni Z, Vlahov D, Nelson L, Nam S.
**COVID-19 Vaccine Hesitancy Among Medicare Beneficiaries with and Without Cancer History: A US Population-based Study**
*Journal of Community Health.*

Read More

Jaffe A, Taddei TH, Giannini EG, Ilagan-Ying YC, Colombo M, Strazzaboso M.
**Holistic Management of Hepatocellular Carcinoma: The Hepatologist’s Comprehensive Playbook**

Read More

Han R, Yang H, Ling C, Lu L.
**Tiliroside Suppresses Triple-Negative Breast Cancer as A Multifunctional CAXII Inhibitor**

Read More

Huang J, Harris E, Lorch J.
**Vaccination As a Therapeutic Strategy for Nasopharyngeal Carcinoma**
*Science Direct, Oral Oncology,* 135:106083.

Read More

Moran MS, Ho AY.
**Radiation Therapy for Low-Risk Breast Cancer: Whole, Partial, or None?**
*Journal of Clinical Oncology.*

Read More

Shroff RT, Goodman KA, Mehnert JM, Vose JM, Moran SE, Yessaian JL, Baldo I, Alexander BM, Highsmith OR, Mills JM, Kunz PL.

Read More


Read More


Read More


Read More


Read More

Check DK, Baggett CD, Kim K, Merlin JS, Oeffinger KC, Winn AN, Roberts MC, Robinson T, Dinan MA. Concurrent Prescribing of Opioids with Other Sedating Medications After Cancer Diagnosis: A Population-Level Analysis Supportive Care in Cancer.

Read More


Read More


Read More


Read More

Genetics RIP December 7; 12:00 PM Sterling Hall of Medicine, I-Wing; 304 Katherine Koczwara | Ty Brown Learn More

Yale Cancer Center Special Seminar December 7; 3:15 PM Evaluation of MTAP Expression for the Diagnosis of Pancreatic Ductal Adenocarcinoma in Fine Needle Aspiration Cell Block and Core Needle Biopsy Specimens Sanhong Yu, MD, PhD Learn More

CBDS Distinguished Speaker Seminar December 7; 4:00 PM Scalable Integrative Analysis of Large Biobank and Population-Based Whole Genome Sequencing Studies with Multi-Omics Data Xihong Lin, PhD Learn More

Building Against Burnout December 8; 12:15 PM Upgrade Highlights Ritche Manos Hao, MD, BS Learn More

Digestive Diseases Pathophysiology Seminar December 9; 1:00 PM Familial Colon Cancer Syndromes Xavier Llor, MD, PhD Learn More

Yale Cancer Answers December 11; 7:30 PM The Role of Surgical Oncology in Treating Metastatic Cancers Kiran Turaga, MD, MPH Learn More

Genetics Seminar Series December 13; 11:30 AM The Anlyan Center; N107 Regulation of C. Elegans Primordial Germ Cells by Niche Cell Interactions and Basement Membrane Signals Jeremy F. Nance, PhD Learn More
Li X, Yan H, Wu J, Zhang L.
Tobacco Smoking Associates with NF1 Mutations Exacerbating Survival Outcomes in Gliomas
Biomarker Research, 10(1):78.
Read More

Prediction Of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancer: Development And External Validation Of A Multi-Institutional Model
Science Direct, Journal of Thoracic Oncology, online ahead of print.
Read More

Potnis KC, Di M, Isufi I, Gowda L, Seropian SE, Foss FM, Forman HP, Huntington SF.
Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Adults with Relapsed or Refractory Follicular Lymphoma
Blood Advances.
Read More

Mandell JD, Fisk JN, Cyrenne E, Xu ML, Cannataro VL, Townsend JP.
Not Only Mutations But Also Tumorigenesis Can Be Substantially Attributed To DNA Damage From Reactive Oxygen Species In RUNX1::RUNX1T1-Fusion-Positive Acute Myeloid Leukemia
Leukemia.
Read More

Black EM, Joo YK, Kabeche L.
Keeping Relapse in Chk: Molecular Mechanisms of Chk1 Inhibitor Resistance in Lymphoma
Biochemical Journal, 479(22):2345-2349.
Read More

Gaddy J, Gross C.
Addressing Racial, Ethnic, and Age Disparities in Cancer Clinical Trial Enrollment: Time to Stop Tinkering Around the Edges
JAMA Oncology.
Read More

Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
Read More
Funding and Award Opportunities

**BCA Education and Outreach Grants**
Breast Cancer Alliance offers grants to support programs directly related to outreach and case managerial breast cancer services, including education, counseling, biopsies and mammograms for the underserved. The programs must be located in Connecticut and/or in Westchester County, New York.

**Application Deadline:** December 9, 2022

Read More

**AHEAD (Advancing Head and Neck Cancer Early Detection Research) (U01)**
The purpose of this FOA is to accelerate translation of research to improve early detection of head and neck cancers (HNC). This FOA seeks applications that focus on early detection of HNC by applying molecular, cellular, and multi-omics signatures to clinical studies for differentiating benign from premalignant lesions, and identifying prognostic signatures on the transformation from premalignant to malignant lesions.

**Letter of Intent Due:** December 11, 2022

Read More

**Alex's Lemonade Stand Foundation 2023 Young Investigator Grant**
The Young Investigator grant is a three-year award designed to support early career researchers, such as postdoctoral fellows, clinical fellows or instructors, pursuing promising childhood cancer research ideas. These grants aim to cultivate the best and brightest researchers of the future who demonstrate a commitment to a research career in pediatric cancer. A mentor is required, and a career development plan must be included. The Young Investigator grant offers up to $50,000 in direct costs per year for three years.

**Application Deadline:** December 12, 2022

Read More

**NCI Intramural Continuing Umbrella of Research Experiences (iCURE)**
This program supports mentored research experiences for qualified students and scientists from diverse backgrounds in the multidisciplinary research environment of the NCI campuses in Bethesda, Rockville, and Frederick, Maryland.

**Application Deadline:** December 15, 2022

Read More

**2023 Mary Kay Ash Foundation Innovative/Translational Cancer Research Grant**
The Mary Kay Ash FoundationSM, a funding source for cancer research, is currently accepting applications for innovative grants for translational research for cancers affecting women, including but not limited to ovarian, uterine, breast and/or cervical cancer. Grants will be awarded in the amount of $100,000 over a two-year period.

**Internal Submission Deadline:** December 19, 2022 at 3:00 pm

Read More
**Basser Center for BRCA: 2023 External Research Grant Program**
The Basser Center for BRCA at Penn Medicine’s Abramson Cancer Center announces the Basser External Research Grant Program, which focuses on projects that have the potential to advance the care of individuals living with BRCA1 and BRCA2 mutations. Research grant applications in basic science, prevention, disease interception, and early detection and relevant to the study of BRCA1/2 will be considered.

**Letters of Intent Due:** December 19, 2022

**Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20)**
Through this FOA, the NCI invites P20 planning grant applications for developing collaborative partnerships between institutions serving health disparity populations and underrepresented students (ISUPs) and NCI-designated Cancer Centers (or Cancer Centers with highly integrated cancer research programs). This FOA is designed to facilitate the planning and execution of focused collaborations in cancer-related research, research experience, and research education.

**Application Deadline:** January 6, 2023

**Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54)**
This funding opportunity seeks to support the Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) Program. The CPACHE Program develops and maintains comprehensive, long-term, and mutually beneficial partnerships between institutions serving underserved health disparity populations and underrepresented students and NCI-designated Cancer Centers. The program aims to achieve a stronger national cancer program and address challenges in cancer and cancer disparities research, education, and outreach, as well as cancer’s impact on underserved populations.

**Application Deadline:** January 6, 2023

**DeLuca Pilot Award**
5 pilot awards will be awarded to support investigators pursuing research in Hematology and to generate preliminary data for new NCI/NIH grant applications. The research should seek to advance our knowledge in Hematologic disorders and to improve patient care, therapies, and outcomes. For more information, please contact Richard.Carr@yale.edu

**Letter of Intent Due:** January 9, 2023

**Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Liquid Biopsy Research Laboratories (U01/U24)**
The purpose of this FOA is to solicit applications for Liquid Biopsy Research Laboratories (LBRLs), one of the two components of the Precompetitive Collaboration on Liquid Biopsy for Early-Cancer Assessment Consortium (LBC). The LBRLs will conduct research on the development of liquid biopsy technologies, assays and/or methods for the capture and analysis of tumor associated cells, DNA, RNA, or exosomes in body fluids of individuals with early-stage cancer or at high risk of developing the disease.

**Application Deadline:** January 10, 2023
**CRI Lloyd J. Old STAR Program**
The CRI Lloyd J. Old STAR Program—Scientists TAKing Risks—provides long-term funding to mid-career scientists, giving them the freedom and flexibility to pursue high-risk, high-reward research at the forefront of discovery and innovation in cancer immunotherapy.

**Deadline for Applications:** January 15, 2023

**Read More**

**Breast Cancer Research Foundation Precision Prevention Initiative**
The overarching goal of the 2023 BCRF Precision Prevention Initiative is to fuel innovation and accelerate breast cancer prevention research by challenging the research community to think boldly; to explore multidisciplinary approaches to get the answers in less time, utilize new technologies or identify new ways to examine available data, and to build or enhance infrastructure, resources, and tools that will facilitate innovation in prevention research for years to come.

**Letter of Intent Due:** January 16, 2023

**Read More**

**Measures and Methods to Advance Research on Minority Health and Health Disparities-Related Constructs (R01)**
The purpose of this FOA is to support research that will advance the measurement and methodology of complex constructs relevant to minority health and health disparities.

**Application Deadline:** February 5, 2023

**Read More**

**NCI Cancer Moonshot Scholars Diversity Program (CMSDP) (R01)**
This Funding Opportunity Announcement (FOA) supports the Cancer Moonshot Scholars Diversity Program (CMSDP) and solicits R01 grant applications that propose independent research projects within the scientific mission of the National Cancer Institute (NCI). The overarching goal of the CMSDP is to increase the number of R01 Early Stage Investigators (ESIs) and enhance the diversity of the cancer research workforce, while promoting scientific advancements in cancer. Investigators from diverse backgrounds, including those from underrepresented groups are encouraged to work with their institutions to apply.

**Application Deadline:** February 6, 2024

**Read More**

**Transformative Educational Advancement and Mentoring Network (TEAM) (R25)**
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

**Application Deadline:** February 10, 2023

**Read More**

**Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01)**
The purpose of this FOA is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the...
biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence.

**Application Deadline:** February 21, 2023

Read More

**Pathway to Independence Award in Tobacco Regulatory Research (K99/R00)**
The purpose of this FOA is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing.

**Application Deadline:** February 21, 2023

Read More

**NCI Cancer Screening Research Network Funding Opportunities**
The CSRN conducts rigorous, multi-center cancer screening trials and studies with large and diverse populations in a variety of health care settings with the goal of reducing cancer incidence and cancer-related morbidity and mortality. Cancer screening provides a unique opportunity to diagnose cancers and pre-cancerous lesions before symptoms develop.

- **ACCrual, Enrollment, and Screening Sites (ACCESS) Hub (UG1)**
- **Statistics and Data Management Center (UG1)**
  - Coordinating and Communication Center (UG1)

**Application Deadlines:** February 28, 2023

**JH Milstone Fund Grant**
JH Milstone Fund will award a grant in 2023 to support early-stage investigators and innovative research that improves understanding of bleeding, thrombosis or thrombolysis.
The research can focus on the genetics, biochemistry or cell biology of coagulation or thrombolysis or on the causes, pathogenesis, diagnosis or treatment of bleeding and clotting disorders. In the absence of preliminary data, appropriate mentors and/or collaborators are important. For more information, please contact Richard.Carr@yale.edu

**Letter of Intent Due:** March 1, 2023

Read More

**DeLuca Career Development Award**
The purpose of this career development award is to provide early career clinical or laboratory-based investigators in Hematology, the opportunity to focus on research to advance patient care, therapies, and outcomes and with the goal to achieve independent support for their research from a national agency. For more information, please contact Richard.Carr@yale.edu

**Letter of Intent Due:** March 1, 2023

Read More

**AHEAD (Advancing Head and Neck Cancer Early Detection Research) (U01)**
The goal of this FOA is to accelerate translation of research to improve early detection of head and neck cancers (HNC). This initiative will encourage development, evaluation, and validation of biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early HNC.

**Application Deadline:** March 14, 2023

Read More
Diversity and Inclusion in Breast Cancer Research

The following research awards are designed with the primary goal of increasing diversity in the oncology workforce and breast cancer research. These awards are made possible through the support of the Breast Cancer Research Foundation (BCRF).

- **Career Development Award**: Full Application Due: March 13, 2023
- **Young Investigator Award**: Full Application Due: March 13, 2023

**Joint SPORE Developmental Research Program (DRP) Award – Cancer Disparities**

The YCC Translational Research Office in collaboration with the Yale SPORE in Lung Cancer (YSILC) and the Yale Head and Neck SPORE (YHN-SPORE) have launched a new DRP award to provide support up to $50,000 for a translational pilot project focused on **disparities-related cancer research** in the field of Head and Neck and/or Lung cancer. Studies with a strong translational or clinical component that have the potential to evolve into, or be incorporated into, a full SPORE project and projects with multi-disciplinary collaborations and/or community-based participatory research studies are encouraged.

We encourage to submit your letter of intent (LOI) to **anna.arnal@yale.edu**

There is no deadline to apply, LOIs will be reviewed and eligible applicants will be invited to submit a full application online.